Home Tools
Log in
Cart

Thrombopoietin Receptor

The thrombopoietin receptor also known as the myeloproliferative leukemia protein or CD110 (Cluster of Differentiation 110) is a protein that in humans is encoded by the MPL (myeloproliferative leukemia virus) oncogene.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
TQ0223 Lusutrombopag 1110766-97-6 99.74%
Lusutrombopag
Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocyt...
T7417 Avatrombopag 570406-98-3 99.41%
Avatrombopag
Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and...
T67894 Butyzamide 1110767-45-7 100%
Butyzamide
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which pr...
T3882 4”-O-Glucosylvitexin 76135-82-5 98%
4”-O-Glucosylvitexin
4”-O-Glucosylvitexin (glucosylvitexin) inhibits TPO activity.
Lusutrombopag
TQ0223
Lusutrombopag (Mulpleta) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocyt...
Avatrombopag
T7417
Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and...
Butyzamide
T67894
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which pr...
4”-O-Glucosylvitexin
T3882
4”-O-Glucosylvitexin (glucosylvitexin) inhibits TPO activity.
TargetMol